BR112019004322A2 - moduladores de receptor glicocorticoide para tratar câncer pancreático - Google Patents

moduladores de receptor glicocorticoide para tratar câncer pancreático

Info

Publication number
BR112019004322A2
BR112019004322A2 BR112019004322A BR112019004322A BR112019004322A2 BR 112019004322 A2 BR112019004322 A2 BR 112019004322A2 BR 112019004322 A BR112019004322 A BR 112019004322A BR 112019004322 A BR112019004322 A BR 112019004322A BR 112019004322 A2 BR112019004322 A2 BR 112019004322A2
Authority
BR
Brazil
Prior art keywords
steroidal
azadecaline
fused
grm
sgrm
Prior art date
Application number
BR112019004322A
Other languages
English (en)
Inventor
Hunt Hazel
S Block Thaddeus
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of BR112019004322A2 publication Critical patent/BR112019004322A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

revelam-se métodos e composições para tratar paciente que hospede tumor pancreático não secretor de acth. os métodos compreendem administrar ao paciente agente quimioterapêutico e modulador de receptores glicocorticoides (grm, sigla em inglês para glucocorticoid receptor modulator), preferencialmente modulador seletivo de receptor glicocorticoide (sgrm), para reduzir a carga tumoral no paciente. o grm pode ser grm não esteroide e pode ser sgrm não esteroide. o tumor pancreático não secretor de acth pode ser tumor pancreático exócrino. o sgrm não esteroide pode ser composto não esteroide que compreenda: estrutura de azadecalina fundida; estrutura de azadecalina fundida com heteroarilcetona; ou estrutura de azadecalina fundida com octahidro. são reveladas composições farmacêuticas que compreendem agente quimioterapêutico e grm. o grm em tais composições farmacêuticas pode ser grm não esteroide, e pode ser sgrm, tal como sgrm não esteroide. o sgrm não esteroide pode compreender: estrutura de azadecalina fundida; estrutura de azadecalina fundida com heteroarilcetona; ou estrutura de azadecalina fundida com octahidro
BR112019004322A 2016-09-09 2017-09-08 moduladores de receptor glicocorticoide para tratar câncer pancreático BR112019004322A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662385590P 2016-09-09 2016-09-09
PCT/US2017/050812 WO2018049255A1 (en) 2016-09-09 2017-09-08 Glucocorticoid receptor modulators to treat pancreatic cancer

Publications (1)

Publication Number Publication Date
BR112019004322A2 true BR112019004322A2 (pt) 2019-05-28

Family

ID=61558939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004322A BR112019004322A2 (pt) 2016-09-09 2017-09-08 moduladores de receptor glicocorticoide para tratar câncer pancreático

Country Status (13)

Country Link
US (8) US9943505B2 (pt)
EP (1) EP3509584A4 (pt)
JP (3) JP7003117B2 (pt)
KR (1) KR102424221B1 (pt)
CN (1) CN109689044B (pt)
AU (1) AU2017323636B2 (pt)
BR (1) BR112019004322A2 (pt)
CA (1) CA3034114C (pt)
IL (1) IL265217B2 (pt)
MX (2) MX2019002703A (pt)
PH (1) PH12019500475A1 (pt)
WO (1) WO2018049255A1 (pt)
ZA (1) ZA201901135B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2869172T3 (es) 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
AU2018244928B2 (en) * 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
SG11202107075RA (en) * 2019-01-22 2021-08-30 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired skin wound healing
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2020367769B2 (en) * 2019-10-16 2023-10-12 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
US20230358768A1 (en) 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
IL294953A (en) * 2020-02-10 2022-09-01 Corcept Therapeutics Inc Methods for inducing an antitumor response using a selective glucocorticoid receptor modulator
US11561387B2 (en) 2020-03-12 2023-01-24 Integrated Endoscopy, Inc. Endoscope designs and methods of manufacture
EP4153770A2 (en) 2020-05-22 2023-03-29 Promega Corporation Enhancement of kinase target engagement
MX2022014923A (es) 2020-05-27 2023-01-04 Corcept Therapeutics Inc Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9.
IL298151A (en) 2020-05-27 2023-01-01 Corcept Therapeutics Inc Concomitant Administration of a Recorrelating Glucocorticoid Receptor Modulator and Cyp2c8 Substrates
WO2021242912A1 (en) * 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
US20240091385A1 (en) * 2022-09-02 2024-03-21 Corcept Therapeutics Incorporated Methods of assessing selective glucocorticoid receptor modulation and of identifying and treating patients likely to benefit from glucocorticoid receptor modulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313317T3 (es) * 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
TW200741192A (en) 2006-03-10 2007-11-01 Koninkl Philips Electronics Nv Methods and systems for identification of DNA patterns through spectral analysis
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012106514A2 (en) 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
PT3111950T (pt) 2012-02-24 2021-10-19 Univ Chicago Métodos e composições relacionadas com antagonismo recetor de glucocorticoide e cancro da próstata
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT4119561T (pt) 2012-05-25 2024-09-30 Corcept Therapeutics Incorporated Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
ES2869172T3 (es) 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
CA2973819A1 (en) 2014-12-19 2016-06-23 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
KR20180116372A (ko) 2016-03-01 2018-10-24 코어셉트 쎄라퓨틱스, 잉크. 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Also Published As

Publication number Publication date
AU2017323636A1 (en) 2019-03-07
US10449178B2 (en) 2019-10-22
IL265217B (en) 2022-12-01
EP3509584A1 (en) 2019-07-17
US10213414B2 (en) 2019-02-26
KR102424221B1 (ko) 2022-07-21
US20230285361A1 (en) 2023-09-14
US20200000771A1 (en) 2020-01-02
IL265217B2 (en) 2023-04-01
US9943505B2 (en) 2018-04-17
US20190151288A1 (en) 2019-05-23
CN109689044B (zh) 2021-08-10
EP3509584A4 (en) 2020-04-29
MX2019002703A (es) 2019-08-01
JP2021050242A (ja) 2021-04-01
US20180071255A1 (en) 2018-03-15
JP2022105213A (ja) 2022-07-12
JP7174083B2 (ja) 2022-11-17
US20180193313A1 (en) 2018-07-12
US10117852B2 (en) 2018-11-06
JP2019530666A (ja) 2019-10-24
AU2017323636B2 (en) 2020-04-02
IL265217A (en) 2019-05-30
PH12019500475A1 (en) 2019-07-29
CA3034114A1 (en) 2018-03-15
US10828280B2 (en) 2020-11-10
MX2022001583A (es) 2022-03-11
US11642331B2 (en) 2023-05-09
CN109689044A (zh) 2019-04-26
JP7003117B2 (ja) 2022-02-10
US20210030717A1 (en) 2021-02-04
US20200230107A1 (en) 2020-07-23
US20190030001A1 (en) 2019-01-31
WO2018049255A1 (en) 2018-03-15
CA3034114C (en) 2021-11-09
US10646474B2 (en) 2020-05-12
ZA201901135B (en) 2020-07-29
KR20190040511A (ko) 2019-04-18

Similar Documents

Publication Publication Date Title
BR112019004322A2 (pt) moduladores de receptor glicocorticoide para tratar câncer pancreático
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
EP4140487A8 (en) Combination therapy for treating cancer
MX2017013983A (es) Uso de agentes activos durante tratamientos quimicos.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2017013142A (es) Terapia combinada para tratar cáncer.
JO3606B1 (ar) معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112018006817A2 (pt) método de tratamento do câncer
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
BR112018002530A2 (pt) combinações e usos e tratamentos destas
BR112017018198A2 (pt) inibição da atividade de olig2
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
BR112015032728A2 (pt) formulação compósita em cápsula farmacêutica compreendendo tadalafil e tansulosina
BR112018011045A2 (pt) inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
BR112018068296A2 (pt) indutores de molécula pequena de espécies de oxigênio reativas e inibidores de atividade mitocondrial

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]